IconMEX:ICLRN 87 Buyback Yield % is 3.84 as of Jun. 27, 2026, which is 113% above its 10-year median of 1.80. GuruFocus rates MEX:ICLRN with a GF Score™ of 87/100 and a GF Value™ of MXN2,479.74. The stock has 4 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, Icon ranks better than 90.8% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Icon's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ICLRN vs RVTY, CRL, MEDP: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Icon's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Icon Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Icon's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Icon's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Icon (MEX:ICLRN) has a Buyback Yield % of 3.84 as of Jun. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Icon and its competitors. This is 113% above median its historical median of 1.80. Over the past decade, Icon's Buyback Yield % has ranged from 0.51 to 5.90. According to the industry distribution chart, Icon ranks #8 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 9.2%.
Is Icon's Buyback Yield % too high?
Icon's current Buyback Yield % of 3.84 is 113% above median its 10-year median of 1.80. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 5.90. Based on the distribution chart, Icon ranks #8 out of 87 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Icon has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Icon's Buyback Yield % compare to RVTY and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Icon ranks #8 out of 87 companies for Buyback Yield %. This places Icon in the top 9% of its industry — outperforming the majority of peers. Historically, Icon's own Buyback Yield % has ranged from 0.51 to 5.90 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Icon and its competitors. Icon's current Buyback Yield % is 3.84, which is 113% above median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Icon stock overvalued right now?
Icon (MEX:ICLRN) has a current Buyback Yield % of 3.84. The stock's GF Value™ is MXN2,479.74, compared to a current price of MXN1,850.28 — trading 25.4% below its estimated fair value. The current Buyback Yield % is 3.84, which is 113% above median its 10-year median of 1.80. Icon's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Icon (MEX:ICLRN), the current Buyback Yield % is 3.84 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Icon (MEX:ICLRN) Overvalued in 2026?
Based on GuruFocus' analysis, Icon stock appears to be undervalued.
The current stock price of MXN1,850.28 is trading 25.4% below its estimated GF Value™ of MXN2,479.74.
Key valuation signals for MEX:ICLRN:
Buyback Yield %: 3.84 (113% above median its 10-year median of 1.80)
GF Value™: MXN2,479.74 vs. price of MXN1,850.28 (25.4% below fair value)
No single metric tells the full story. See the MEX:ICLRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
87GF Score
Get the complete analysis for MEX:ICLRN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ICLRN has been successfully added to your 
